Corealis Pharma has acquired a new 33,000-sq.-ft. pharmaceutical research facility in the Cité de la Biotech in Laval, Quebec, Canada. The company is hiring highly skilled scientists and purchasing complementary analytical and manufacturing equipments. These investments are part of Corealis’ ongoing strategic development plan to be recognized as “the reference in oral solid dosage formulation development,” according to a company statement.

Dr. Yves Roy, president of Corealis Pharma, remarked, “In the last few years, we have had to decline projects on a regular basis. With these investments, we will now be able to consolidate all of our services under one roof, tighten our project timelines, increase our capacity, reduce our operating costs and triple our yearly capacity. To our customers, this means shorter development time for their drug products. As a result, they will get noticed faster by large pharma for potential acquisition or partnership. We strive to make our clients succeed and I believe that we have now taken actions that will further help them achieve their goals!”

Corealis is maintaining all the existing quality systems active in the facility to offer services that comply with the Health Canada, FDA and EMEA Pharmaceutical GMP requirements.